TNFRSF10B and ovarian carcinoma: While recombinant DR5 has shown efficacy in inducing cell death in ovarian cancer cell lines in vitro, its clinical translation may be limited by factors such as systemic toxicity, short half-life, and off-target effects [66,67,85].